Scancell Holdings plc (AIM: SCLP), a clinical stage biopharmaceutical company, reported on Tuesday that it has dosed the first patient with iSCIB1+ and doublet checkpoint inhibitor therapy, consisting of ipilimumab (Yervoy) plus nivolumab (Opdivo) in the SCOPE trial, marking a significant milestone in cancer immunotherapy.

iSCIB1+ is an enhanced version of SCIB1 developed to broaden effectiveness beyond specific tissue types. With similarities to SCIB1, iSCIB1+ is anticipated to yield exceptional results, targeting a broader range of melanoma patients. The trial's early data is expected by Q4 2024.

These advancements pave the way for a Phase 2/3 seamless adaptive registration programme targeting unresectable melanoma, a market estimated at USD1.5bn annually.

Scancell utilises innovative platforms like Moditope, ImmunoBody, GlyMab and AvidiMab to develop novel medicines addressing significant unmet needs in cancer and infectious diseases. Its unique approach leverages adaptive immune responses to induce immune reactions or redirect immune cells, targeting modifications of proteins and lipids for enhanced therapeutic efficacy.